Harpoon Therapeutics, Inc. (NASDAQ:HARP) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP) have been given a consensus recommendation of “Hold” by the six analysts that are currently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $27.25.

Several brokerages have issued reports on HARP. Citigroup reissued a “neutral” rating and issued a $23.00 price target (up previously from $13.00) on shares of Harpoon Therapeutics in a report on Monday, February 26th. Leerink Partnrs cut shares of Harpoon Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, January 8th. Oppenheimer reissued an “outperform” rating on shares of Harpoon Therapeutics in a report on Tuesday, March 26th. TD Cowen reaffirmed a “market perform” rating on shares of Harpoon Therapeutics in a research note on Tuesday, January 16th. Finally, HC Wainwright lowered Harpoon Therapeutics from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $12.00 to $23.00 in a research note on Monday, January 8th.

Insiders Place Their Bets

In other Harpoon Therapeutics news, major shareholder Merck & Co., Inc. bought 21,397,205 shares of the stock in a transaction dated Monday, March 11th. The stock was bought at an average cost of $23.00 per share, for a total transaction of $492,135,715.00. Following the completion of the purchase, the insider now owns 1,000 shares in the company, valued at approximately $23,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 17.00% of the company’s stock.

Institutional Trading of Harpoon Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of HARP. New Leaf Venture Partners L.L.C. boosted its position in Harpoon Therapeutics by 489.0% in the 4th quarter. New Leaf Venture Partners L.L.C. now owns 1,859,168 shares of the company’s stock valued at $21,139,000 after buying an additional 1,543,500 shares during the last quarter. BlackRock Inc. increased its position in Harpoon Therapeutics by 5.6% in the first quarter. BlackRock Inc. now owns 1,809,686 shares of the company’s stock worth $8,994,000 after purchasing an additional 95,355 shares during the period. Commodore Capital LP bought a new stake in Harpoon Therapeutics during the 4th quarter worth about $17,055,000. Franklin Resources Inc. lifted its position in Harpoon Therapeutics by 1,027.8% during the 4th quarter. Franklin Resources Inc. now owns 1,492,368 shares of the company’s stock valued at $16,968,000 after purchasing an additional 1,360,041 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Harpoon Therapeutics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 1,288,202 shares of the company’s stock valued at $6,402,000 after purchasing an additional 34,392 shares during the last quarter. Institutional investors and hedge funds own 74.01% of the company’s stock.

Harpoon Therapeutics Trading Up 0.1 %

Shares of NASDAQ:HARP opened at $23.01 on Friday. The business’s 50 day moving average is $22.85 and its 200-day moving average is $15.22. The firm has a market capitalization of $389.61 million, a PE ratio of -2.63 and a beta of 2.11. Harpoon Therapeutics has a 1-year low of $3.11 and a 1-year high of $23.21.

Harpoon Therapeutics Company Profile

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma.